Diasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research Congress
Latest Updates

Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin

Latest Updates

News

Diasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research Congress

Read More

Diasome Pharmaceuticals Strengthens Leadership Team as Company Prepares for Phase 3 Development

Read More

WKYC: "A smarter insulin, better meal timing and the avocado test"

Read More

CareTalk Podcast: "Targeting the Root Causes of Metabolic Disease w/ Bob Geho, Founder & CEO, Diasome”

Read More
View All